| Phillip Lynn Nichols Ii, MD | |
|
2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 | |
| (865) 588-8831 | |
| Not Available |
| Full Name | Phillip Lynn Nichols Ii |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 29 Years |
| Location | 2240 Sutherland Ave, Knoxville, Tennessee |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639115496 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 37082 (Tennessee) | Primary |
| 207RS0012X | Internal Medicine - Sleep Medicine | 37082 (Tennessee) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Medical Center Of Oak Ridge | Oak ridge, TN | Hospital |
| Sweetwater Hospital Association | Sweetwater, TN | Hospital |
| Fort Sanders Regional Medical Center | Knoxville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Statcare Outpatient Llc | 2264704055 | 32 |
| Sweetwater Hospital Association | 6608773775 | 25 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
| Entity Name | Statcare Inpatient Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477086981 PECOS PAC ID: 5496025074 Enrollment ID: O20170714002608 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
| Entity Name | Statcare Outpatient Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134653892 PECOS PAC ID: 2264704055 Enrollment ID: O20170814001441 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
| Entity Name | Sweetwater Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558995399 PECOS PAC ID: 6608773775 Enrollment ID: O20210226000607 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Phillip Lynn Nichols Ii, MD Po Box 94670, Oklahoma City, OK 73143-4670 Ph: (405) 682-3303 | Phillip Lynn Nichols Ii, MD 2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 Ph: (865) 588-8831 |
News Archive
ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.
The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people's lives and to examine cases of alleged discrimination.
Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.
Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.
At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.
› Verified 5 days ago
Corey Cudzilo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 Phone: 865-588-8831 Fax: 865-588-8841 | |
Dr. Joshua Weber Todd, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1819 W Clinch Ave, Suite 108, Knoxville, TN 37916 Phone: 865-546-5111 Fax: 865-541-4018 | |
Rasmi Ajit, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9330 Park West Blvd Ste 402, Knoxville, TN 37923 Phone: 865-690-3003 Fax: 865-374-2143 | |
Dr. Spencer Pugh, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920 Phone: 865-305-9340 Fax: 865-305-9144 | |
Saji Eapen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1415 Old Weisgarber Rd, Suite 200, Knoxville, TN 37909 Phone: 865-934-5800 Fax: 865-934-5801 | |
Jeffrey W Robinson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6600 Nightingale Ln, Knoxville, TN 37909 Phone: 865-632-5885 | |
Dr. Mark D Anderson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy, B100, Knoxville, TN 37920 Phone: 865-544-6570 Fax: 865-544-6576 |